← Back to Clinical Trials
Recruiting NCT05657548

NCT05657548 Study of Sagittal Pelvic Statics in the Sitting Position in Children With Cerebral Palsy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05657548
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de Nīmes
Condition Cerebral Palsy Infantile
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2023-10-30
Primary Completion 2027-10

Eligibility & Interventions

Sex All sexes
Min Age 4 Years
Max Age 17 Years
Study Type OBSERVATIONAL
Interventions
spine and pelvis radiography

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2023-10-30 with a primary completion date of 2027-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Cerebral palsy is the leading cause of motor disability in children. Children with little or no walking (GMFCS III, IV and V) represent 43% of children with cerebral palsy, the majority of whom present pelvic and spinal deformities in the frontal and sagittal planes. However, sagittal pelvic spinal statics have been little studied, especially in the sitting position, which is the functional position of these children. Moreover, there are currently no recommendations on how to perform follow-up radiographs of the spine in children who do not walk much. A better understanding of pelvic and sagittal spinal statics would help prevent deformities and their complications. Standardizing the method of performing pelvic-spinal radiographs in the sitting position will make monitoring of spinal statics more reliable.

Eligibility Criteria

Inclusion Criteria: * Child or adolescent aged 4 to 17 years * Child or adolescent with cerebral palsy GMFCS III, IV or V * Child or adolescent whose parents, or the child if possible, have given free, informed and written consent * Child or adolescent affiliated or beneficiary of a health insurance plan Exclusion Criteria: * Child or adolescent with history of spinal surgery * Child or adolescent with parents unable to give consent * Child or adolescent participating in a therapeutic research study (RIPH 1 or drug study) * Child or adolescent in an exclusion period determined by another study * Child or adolescent under court protection, guardianship or curatorship * Pregnant, parturient or breastfeeding patient

Contact & Investigator

Central Contact

Mélanie PORTE

✉ melanie.porte@chu-nimes.fr

📞 +33 4.66.68.34.59

Principal Investigator

Anissa MEGZARI

STUDY DIRECTOR

Centre Hospitalier Universitaire de Nīmes

Frequently Asked Questions

Who can join the NCT05657548 clinical trial?

This trial is open to participants of all sexes, aged 4 Years or older, up to 17 Years, studying Cerebral Palsy Infantile. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05657548 currently recruiting?

Yes, NCT05657548 is actively recruiting participants. Contact the research team at melanie.porte@chu-nimes.fr for enrollment information.

Where is the NCT05657548 trial being conducted?

This trial is being conducted at Nîmes, France.

Who is sponsoring the NCT05657548 clinical trial?

NCT05657548 is sponsored by Centre Hospitalier Universitaire de Nīmes. The principal investigator is Anissa MEGZARI at Centre Hospitalier Universitaire de Nīmes. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology